The Human Heredity and Health in Africa Consortium (H3A) and GSK’s Africa NCD Open Lab are planning a joint project to study the extent of variation in ADME genes in African populations and explore the impact and possible pharmacological effect of key variants.
The project will be based at the Sydney Brenner Institute for Molecular Bioscience at the University of the Witwatersrand, Johannesburg, with collaborators at GSK and at other partners in H3A. We have novel whole genome sequence data sets generated by H3A projects and this will be an im- portant opportunity to develop further expertise in pharmacogenomic research in Africa. The project is sponsored by GSK’s Afrca NCD Open Lab. We seek to appoint a postdoctoral research fellow at the SBIMB to join our team. The first phase of the project will identify novel candidate variants found in African populations that have significant pharmacogenomic interest. The successful candidate will focus on protein modelling and in silico analysis of some of the the selected variants.
This is a two year project. The postdoctoral position will be for 1 year in the first instance, with renewal for one further year based on satisfactory performance. The starting date will be by mutual agreeemnt, but the sooner the better.
• completion of a PhD in bioinformatics or related discipline within the last 5 years; • experience of protein modelling, including structural modelling;
• good bioinformatics background and programming skills;
• knowledge of pharmacogenomics would be a strong recommendation but not essential.
Informal enquiries can be made to Scott Hazelhurst (email@example.com)
A formal application should be made by sending one PDF document containing: a covering letter; a CV including a publication list and the details of three contactable referees. The publication list should clearly distinguish between refereed journal articles, papers in fully refereed published conference proceedings, and other scientific work. We will start considering application son 18 February.